Print ISSN:-2394-2789
Online ISSN:-2394-2797
CODEN : IJPCN9
Original Article
Author Details :
Volume : 3, Issue : 2, Year : 2016
Article Page : 84-89
Abstract
A convenient new method for simultaneous estimation of Beclomethasone dipropionate and Salbutamol sulphate, with minimum sample pretreatment is described in this paper. The procedure, based on the multivariate analysis of spectral data in the 220?260 nm region by the partial least squares method (based on SIMPLS algorithm) has been evaluated. The evaluation of calibration model is relied on the coefficient of determination (R2) and root mean square error of calibration (RMSEC). The coefficient of determination (R2) for the relationship between actual values and predicted values of both drugs was higher than 0.9930, indicating good accuracy of the developed method while RMSEC values (0.8637) obtained were relatively low which indicate acceptable precision of analytical method. The experimental calibration and validation matrixes were constructed with 55 and 24 samples, respectively. The concentration range considered was 10.0-60.0 ?g/ml for both the drugs. The method was successfully applied for estimation of drugs in pharmaceutical formulation, with no interference with excipients as indicated by the recovery studies. The proposed method is simple, rapid and can be easily used in the quality control of drugs as alternative analysis tools.
Key Words: Chemometric, Partial least square, Beclomethasone dipropionate, Salbutamol sulphate
How to cite : Gandhi S V, Pahade A R, Sutar A S, Kuchekar B S, Tapale S R, Simultaneous estimation of beclomethasone dipropionate and salbutamol sulphate in capsules by chemometric assisted UV-spectrophotometric method. Int J Pharm Chem Anal 2016;3(2):84-89
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.